Antidepressant-like effects of ketamine involve CX<sub>3</sub>CL1/CX<sub>3</sub>CR1 signaling-mediated synaptic plasticity in the mPFC.
Abstract
Ketamine, a non-competitive N-methyl-D-aspartate acid (NMDA) receptor antagonist, produces rapid and sustained antidepressant actions, but the underlying molecular mechanism remains unclear. The CX<sub>3</sub>CL1/CX<sub>3</sub>CR1 signaling is closely related to mood disorders, and this study aims to investigate its role in ketamine's antidepressant actions. We pharmacologically (AZD8797, a selective CX<sub>3</sub>CR1 antagonist) and genetically (intra-mPFC microinjection with AAV-CX<sub>3</sub>CR1-siRNA) manipulated the CX<sub>3</sub>CL1/CX<sub>3</sub>CR1 signaling and investigated their effects on ketamine's antidepressant-like effects in mice treated with corticosterone (Cort), and observed changes in synaptic plasticity in response to these manipulations. We found that 24 h after drug injection, ketamine (10 mg/kg, i.p.) significantly reversed the Cort-induced depression-like behaviors, and inhibited the overexpression of pro-inflammatory cytokines and microglial activation. Ketamine significantly improved the Cort-induced impairment in the dendritic complexity and spine densities. In addition, our ELISA results showed that ketamine significantly inhibited the activation of CX<sub>3</sub>CL1/CX<sub>3</sub>CR1 signaling, and ketamine attenuated the upregulation of CX<sub>3</sub>CR1 and CX<sub>3</sub>CL1 expression in Cort-treated HT22 and BV2 cells in vitro. Furthermore, pretreatment with AZD8797 (0.8 mg/kg, i.p., twice a week) completely blocked ketamine's antidepressant-like behavioral effects and eliminated ketamine-induced enhancement in the synaptic plasticity; intra-mPFC microinjection with AAV-CX<sub>3</sub>CR1-siRNA also prevented ketamine's behavioral effects and beneficial effects on the synaptic plasticity. These findings demonstrated that CX<sub>3</sub>CL1/CX<sub>3</sub>CR1 signaling-mediated synaptic plasticity played essential roles in ketamine's antidepressant-like effects, which opened a new door to targeting chemokines to improve depression symptoms.
Topics & conditions
Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.
Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.